Hyperscale Data shifts to bitcoin-only treasury strategy
Investing.com - Canaccord Genuity has reiterated its Buy rating and $26.00 price target on Kenvue Inc (NYSE:KVUE), the maker of Tylenol. The stock, currently trading at $18.50, shows potential upside according to InvestingPro data, which indicates the company maintains impressive gross profit margins of 58%.
The research firm believes there should be minimal legal risk to Kenvue regarding concerns about acetaminophen use during pregnancy, noting that reputable studies still do not link the pain reliever to autism.
Canaccord Genuity points out that even if causation were established, pregnant women represent only a small portion of potential Tylenol consumers, limiting the financial impact on the company.
The firm identifies public opinion as the largest risk factor for Kenvue, though it notes that sentiment is currently mixed regarding the safety of Tylenol for pregnant women.
Canaccord Genuity also highlighted the Tylenol brand’s resilience, referencing how it survived the 1982 Tylenol murders crisis when the company recalled all products after tampering incidents, yet subsequently regained consumer trust and recaptured its temporarily lost market share.
In other recent news, Kenvue Inc has been at the center of discussions due to concerns about its Tylenol brand. Evercore ISI adjusted its price target for Kenvue to $23.00 from $25.00, maintaining an "In Line" rating, amid apprehensions about a potential link between acetaminophen, Tylenol’s active ingredient, and neurodevelopmental disorders during pregnancy. The Wall Street Journal had earlier reported on a possible connection, prompting a notable drop in Kenvue’s stock value. BofA Securities, however, reiterated a Buy rating with a $25.00 price target, indicating confidence despite the recent downturn. RBC Capital also maintained its Sector Perform rating with a $22.00 price target, highlighting ongoing litigation and regulatory concerns. The Department of Health and Human Services is expected to release a report soon, which may further impact perceptions of Tylenol’s safety. These developments have led to varied responses from analysts, reflecting the uncertainty surrounding the situation.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.